Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy.

J D Cavallerano, M T Cahill, L P Aiello

Journal: Eye (London, England) 2004;18(2):117-25

PMID: 14762400

Abstract

Diabetic retinopathy is a leading cause of acquired visual loss. Current treatment modalities are not effective in all cases and may have side effects. Investigation of the biochemical basis of diabetic retinopathy suggests that future treatments may reverse or halt the progression of diabetic retinopathy, or actually prevent the development of diabetic retinopathy. Pharmacological manipulation of protein kinase C and various growth factors may form the basis of future treatments for diabetic retinopathy.

Address: Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA. [email protected]

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.